The current study aimed to develop a novel liquid chromatographic method based on analytical quality by design to analyze relugolix and its related substances. This study builds upon a comparative review of existing analytical methods, highlighting the absence of a pharmacopoeial standard for relugolix determination. To address this gap, a new method was designed and validated. Method development began with preliminary studies to identify critical method attributes and parameters influencing the analytical process. Design of experiments was employed, using a full factorial design for initial screening, while method optimization was carried out through the central composite design approach. The pH and column temperature were identified as critical parameters, whereas the tailing factor and resolution between relugolix and its amine impurity were key performance attributes. The study adhered to the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use Q2 guidelines, ensuring the method’s reliability for routine pharmaceutical analysis. Additionally, stability-indicating degradation studies were conducted under various stress conditions, with degraded samples analyzed using infrared spectroscopy, liquid chromatography–mass spectrometry, and nuclear magnetic resonance techniques. The developed liquid chromatographic method provides valuable insights into the quality and chemical stability of relugolix and its related substances, supporting the further development and regulatory assessment of the drug.
Nagar P, Sharma AK, Kumar R, Chauhan C, Singhal R, Garg M. Advancing relugolix analysis: A comparative study and AQbD-driven method optimization with stability testing. J Appl Pharm Sci. 2025. Online First. https://doi.org/10.7324/JAPS.2025.239585
1. Belkahla S, Nahvi I, Biswas S, Nahvi I, Ben Amor N. Advances and development of prostate cancer, treatment, and strategies: a systemic review. Front Cell Dev Biol. 2022 Sep 9;10:991330. doi: https://doi.org/10.3389/fcell.2022.991330
2. Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 Update on prostate cancer epidemiology and risk factors—a systematic review. Eur Urol. 2023 Aug;84(2):191–206. doi: https://doi.org/10.1016/j.eururo.2023.04.021
3. Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK564367/
4. Shirley M. Relugolix: a review in advanced prostate cancer. Target Oncol. 2023 Mar;18(2):295–302. doi: https://doi.org/10.1007/s11523-023-00977-3
5. Miwa K, Hitaka T, Imada T, Sasaki S, Yoshimatsu M, Kusaka M, et al. Discovery of 1-{4-[1-(2,6-Difluorobenzyl)-5-[(Dimethylamino)Methyl]-3-(6-Methoxypyridazin-3-Yl)-2,4-Dioxo-1,2,3,4-Tetrahydrothieno[2,3-d]Pyrimidin-6-Yl]Phenyl}-3-Methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor. J Med Chem. 2011 Jul 28;54(14):4998–5012. doi: https://doi.org/10.1021/jm200216q
6. Nakata D, Masaki T, Tanaka A, Yoshimatsu M, Akinaga Y, Asada M, et al. Suppression of the hypothalamic–pituitary–gonadal axis by TAK-385 (Relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. Eur J Pharmacol. 2014;723:167–74. doi: https://doi.org/10.1016/j.ejphar.2013.12.001
7. Markham A. Relugolix: first global approval. Drugs. 2019 Apr;79(6):675–9. doi: https://doi.org/10.1007/s40265-019-01105-0
8. Center for Drug Evaluation and Research. FDA approves relugolix for advanced prostate cancer. Silver Spring, MD: US Food and Drug Administration. [cited 2023 Dec 08]. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-relugolix-advanced-prostate-cancer
9. Orgovyx. Amsterdam, The Netherlands: European Medicines Agency. [cited 2024 July 02]. Available from:
10. Papadasu N. A novel validated stability indicative uplc method for relugolix for the determination of process-related and degradation impurities. Rasayan J Chem. 2024;17:325–36. doi: https://doi.org/10.31788/rjc.2024.1728767
11. Kumar M. Marakatham M, Siva Prasad S, Ravi V, Deepika P, Prathibha Bharathi M. RP-HPLC method development and validation of RELUGOLIX. IJCBS. 2023;24(6):850–5.
12. Immani Ramachandra Rao, Chava Lavanya, Punitha P. A new analytical method for determination and quantification of residual solvents in relugolix api bulk drug by GC-MS method. Res J Pharm Technol. 2023;16:4723–8. doi: https://doi.org/10.52711/0974-360x.2023.00767
13. Gummaluri RK, Karipeddi R. An in-vitro study of a simultaneous method for determining relugolix, norethindrone acetate, and estradiol by UPLC. RASAYAN J Chem. 2023;16(03):1770–9. doi: https://doi.org/10.31788/rjc.2023.1638359
14. Thrinath SR, Lakshmi KS, Krishnan M. Development and validation of a method for studying relugolix and its impurities by UPLC-MS. Acta Chromatographica. 2024;16:1–12. doi: https://doi.org/10.1556/1326.2024.01225
15. Pulletikurthi KM, Annapurna N, Doddipalla R, Vijay R, Rumalla CS, Kaliyaperumal M, et al. Force degradation studies of relugolix: identification, isolation and structure characterization of stress degradation products by using liquid chromatography-mass spectrometry, auto purification mass mediated preparative-high performance liquid chromatography, high resolution mass spectrometry, nuclear magnetic resonance spectroscopy. Spectroscopy Lett. 2022;55(2):128–37. doi: https://doi.org/10.1080/00387010.2022.2029903
16. European Medicines Agency ICH Q14 Guideline on analytical procedure development. ICH. Amsterdam, The Netherlands: European Medicines Agency. [cited 2024 March 08]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/ich-q14-guideline-analytical-procedure-development-step-5_en.pdf
17. Shamim A, Ansari MJ, Aodah A, Iqbal M, Aqil M, Mirza MA, et al. QbD-engineered development and validation of a RP-HPLC method for simultaneous estimation of rutin and ciprofloxacin HCl in bilosomal nanoformulation. ACS Omega. 2023;8(24):21618–27. doi: https://doi.org/10.1021/acsomega.3c00956
18. Sha’at M, Spac AF, Stoleriu I, Bujor A, Cretan MS, Hartan M, et al. Implementation of QbD approach to the analytical method development and validation for the estimation of metformin hydrochloride in tablet dosage forms by HPLC. Pharmaceutics. 2022;14(6):1187. doi: https://doi.org/10.3390/pharmaceutics14061187
19. Patel KG, Patel AT, Shah PA, Gandhi TR. Multivariate optimization for simultaneous determination of aspirin and simvastatin by reverse phase liquid chromatographic method using AQbD approach. Bull Facul Pharm Cairo Univ. 2017;55(2):293–301. doi: https://doi.org/10.1016/j.bfopcu.2017.08.003
20. PubChem. Relugolix. pubchem.ncbi.nlm.nih.gov Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Relugolix
21. Relugolix Amine Impurity Daicel Pharma Standards. 2022. [cited 2024 July 02]. Available from: https://www.daicelpharmastandards.com/product/relugolix/relugolix-amine-impurity
22. Lolla S, Gubbiyappa KS. Bio-analytical method development and validation for the quantitation of relugolix in plasma samples by lc-ms/ms: application to bioavailability study in rabbits. Rasayan J Chem. 2023;16(01):494–501. doi: https://doi.org/10.31788/rjc.2023.1618105
23. PubChem. Relugolix Impurity 17. 2022. [cited 2024 July 02]. Available from: Available from:
24. SitePoint. Simson Pharma Limited. [cited 2024 July 02]. Available from: https://www.simsonpharma.com/us/product/relugolix-impurity-42
25. Center for drug evaluation and research application number: 214621orig1s000 product quality review(s). [cited 2024 July 03]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/214621Orig1s000ChemR.pdf
26. Orgovyx (relugolix) FDA Approval History. [cited 2024 July 03]. Available from: https://www.drugs.com/history/orgovyx.html
27. Taylor MR, Kawakami J, McCalley DV. Managing sample introduction problems in hydrophilic interaction liquid chromatography. J Chromatogr A. 2023 Jul 5;1700:464006. doi: https://doi.org/10.1016/j.chroma.2023.464006
28. Vogt FG, Kord AS. Development of quality-by-design analytical methods. J Pharm Sci. 2011 Mar;100(3):797–812. doi: https://doi.org/10.1002/jps.22325
29. Bains, B. Improve chromatographic separations: consider mobile phase pH & analyte pKa. ACD/Labs Available from: https://www.acdlabs.com/blog/improve-chromatographic-separations-consider-mobile-phase-ph-analyte-pka/
30. Tome T, Obreza A, ?asar Z. Developing an Improved UHPLC method for efficient determination of European pharmacopeia process-related impurities in ropinirole hydrochloride using analytical quality by design principles. Molecules. 2020 Jun 10;25(11):2691. doi: https://doi.org/10.3390/molecules25112691
31. Introduction to MarvinSketch | Chemaxon Docs. docs.chemaxon.com. [cited 2024 July 03]. Available from: https://docs.chemaxon.com/display/lts-europium/introduction-to-marvinsketch.md
32. Tome T, Žigart N, ?asar Z, Obreza A. Development and optimization of liquid chromatography analytical methods by using AQbD principles: overview and recent advances. Organ Process Res Dev. 2019;23(9):1784–802. doi: https://doi.org/10.1021/acs.oprd.9b00238
33. Schiefer H, Schiefer F, Schiefer H. Statistical design of experiments (DoE). Statistics for Engineers: an Introduction with Examples from Practice. 2021. Pp 1–20.doi: https://doi.org/10.1007/978-3-658-32397-4_1
34. Lamidi S, Olalere R, Yekinni A, Adesina K. Design of experiments (DOE): applications and benefits in quality control and assurance. Available from: https://www.intechopen.com/chapters/88829
35. Jensen WA. Response surface methodology: process and product optimization using designed experiments 4th edition. J Qual Technol. 2017;49(2):186–8. doi: https://doi.org/10.1080/00224065.2017.11917988
36. Bhattacharya S. Central composite design for response surface methodology and its application in pharmacy. Shirpur, India: IntechOpen; 2021.
37. Azhakesan A, Kuppusamy S. Analytical quality by design-assisted HPLC method for quantification of canagliflozin and stability studies. ACS Omega. 2023;8(8):7407–14. doi: https://doi.org/10.1021/acsomega.2c06038
38. Harish V, Almalki WH, Alshehri A, Alzahrani A, Gupta MM, Alzarea SI, et al. Quality by design (QbD) based method for estimation of Xanthohumol in bulk and solid lipid nanoparticles and validation. Molecules. 2023;28(2):472. doi: https://doi.org/10.3390/molecules28020472
39. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, ICH Harmonised Guideline Validation Of Analytical Procedures Q2(R2); 2023.
40. Kowalska M, Wo?niak M, Kijek M, Mitrosz P, Szakiel J, Turek P. Management of validation of HPLC method for determination of acetylsalicylic acid impurities in a new pharmaceutical product. Sci Rep. 2022 Jan 6;12(1):1. doi: https://doi.org/10.1038/s41598-021-99269-x
41. Al-Shami N, Naseef H, Moqadi R, Kanaze F. HPLC method development and validation for the determination of Apixaban and Clopidogrel in novel fixed-dose combination tablets. J Chem, 2024;2024:e2675736. doi: https://doi.org/10.1155/2024/2675736
42. Pecchio M, Salman H, Irache JM, Renedo MJ, Dios-Viéitez MC. Development and validation of a HPLC method for the determination of cyclosporine a in new bioadhesive nanoparticles for oral administration. Indian J Pharm Sci. 2014 Mar;76(2):132–7.
43. Amer SM, Kadi AA, Darwish HW, Attwa MW. LC–MS/MS method for the quantification of Masitinib in RLMs matrix and rat urine: application to metabolic stability and excretion rate. Chem Central J. 2017 Dec 22;11(1):136. doi: https://doi.org/10.1186/s13065-017-0365-2
44. Kadi AA, Darwish HW, Attwa MW, Amer SM. Validated LC-MS/MS method for the quantification of Ponatinib in plasma: application to metabolic Stability. PLoS One. 2016 Oct 20;11(10):e0164967. doi: https://doi.org/10.1371/journal.pone.0164967
45. Kovac? L, C?asar Z, Trdan Lus?in T, Ros?kar R. Development of an analytical method for determination of related substances and degradation products of Cabotegravir using analytical quality by design principles. ACS Omega. 2022;7(10):8896–905. doi: https://doi.org/10.1021/acsomega.1c07260
46. Naseef H, Moqadi R, Qurt M. Development and validation of an HPLC method for determination of antidiabetic drug Alogliptin Benzoate in bulk and tablets. J Anal Methods Chem. 2018 Sep 24;2018:1902510. doi: https://doi.org/10.1155/2018/1902510
47. Dosugi NF, Elbashir AA. Development and validation of reverse phase high performance liquid chromatography with fluorescence detector (RP-HPLC-FL) method for the determination of gemifloxacin in pharmaceutical dosage forms. Biomedical J Sci Tech Res. 2022;43(3):34527–32. doi: https://doi.org/10.26717/BJSTR.2022.43.006895
48. Gholve R, Pekamwar S, Wadher S, Kalyankar T. Stability-indicating RP-HPLC method development and validation for simultaneous estimation of Telmisartan and Rosuvastatin calcium in bulk and in tablet dosage form. Future J Pharm Sci. 2021;7(1):1–5. doi: https://doi.org/10.1186/s43094-021-00369-2
49. Dabhi B. Method development and validation of a stability-indicating RP-HPLC method for the quantitative analysis of Dronedarone hydrochloride in pharmaceutical tablets. Scia Pharm. 2013;81(1):115–22. doi: https://doi.org/10.3797/scipharm.1209-15
50. Jahan MS, Islam MJ, Begum R, Kayesh R, Rahman A. A study of method development, validation, and forced degradation for simultaneous quantification of paracetamol and Ibuprofen in pharmaceutical dosage form by RP-HPLC method. Anal Chem Insights. 2014 Nov 18;9:75–81. doi: https://doi.org/10.4137/aci.s18651
51. Blessy M, Patel RD, Prajapati PN, Agrawal YK. Development of forced degradation and stability indicating studies of drugs—a review. J Pharm Anal. 2014;4(3):159–65. doi: https://doi.org/10.1016/j.jpha.2013.09.003
52. Zaman B, Hassan W. Development of stability indicating HPLC–UV method for determination of daclatasvir and characterization of forced degradation products. Chromatographia. 2018;81(5):785–97. doi: https://doi.org/10.1007/s10337-018-3503-7
53. Venkata Rao P. A novel, validated stability-indicating UPLC method for the estimation of Lansoprazole and its impurities in bulk drug and pharmaceutical dosage forms. Sci Pharm. 2013;81(1):183–93. doi: https://doi.org/10.3797/scipharm.1210-09
Year
Month